Releases

Print
2013
2012
2011
2010
2009
Archives

Category:

All
ı
Corporate Releases
ı
Press Releases
ı
Releases in Danish
Dec 23, 2010
Press Releases

Lundbeck appoints vice president of global product strategy

Dec 16, 2010
Corporate Releases

Lundbeck enters into drug discovery collaboration with Zenobia and Vernalis

Dec 14, 2010
Corporate Releases

Lundbeck to establish a strong, dedicated sales force behind Lexapro® in China as part of a new co-promotion agreement

Dec 4, 2010
Corporate Releases

Lundbeck reports positive phase III study results for clobazam in the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome

Nov 23, 2010
Corporate Releases

Financial calendar 2011

Nov 19, 2010
Press Releases

Lundbeck appoints vice president of strategic alliances

Nov 4, 2010
Corporate Releases

Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities

Nov 3, 2010
Corporate Releases

Lundbeck expects to deliver solid profits during a period of new product launches and patent expiries

Nov 3, 2010
Corporate Releases

Third quarter report 2010 -- Continued strong growth in third quarter - 2010 results to be at the high end of guidance range

Oct 13, 2010
Corporate Releases

Lundbeck and Genmab enter into a research collaboration

Oct 12, 2010
Corporate Releases

Lundbeck and Merck sign exclusive commercialisation agreement for SYCREST® (asenapine) sublingual tablets in all markets outside of the United States, China and Japan

Oct 5, 2010
Corporate Releases

Lundbeck enters into license agreement with Kyowa Hakko Kirin for A2a antagonists for Parkinson's and other indications

Sep 22, 2010
Press Releases

Lundbeck launches new research and development strategy

Sep 15, 2010
Corporate Releases

Escitalopram filed in Japan

Sep 9, 2010
Corporate Releases

Lundbeck wins Federal Trade Commission case in Federal District Court

Aug 13, 2010
Corporate Releases

First half report 2010 - Lundbeck reports strongly increasing profits with EBIT growth of 30%

Aug 5, 2010
Corporate Releases

TEMPO study further demonstrates the benefits of Azilect® in early Parkinson's disease patients

May 27, 2010
Corporate Releases

First patients recruited in the extended phase III programme using Lu AA21004 in MDD

May 25, 2010
Corporate Releases

Lundbeck will submit an NDA for clobazam for patients with Lennox-Gastaut syndrome with the FDA before year end 2010

May 17, 2010
Corporate Releases

Positive pivotal results on escitalopram in Japan - Lundbeck's partner Mochida plans to file escitalopram for regulatory approval in first quarter 2011 at the latest

May 10, 2010
Corporate Releases

Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities

May 6, 2010
Corporate Releases

First Quarter Report 2010 - Lundbeck delivers strong growth - and is off to a very good start to achieve full year guidance

Apr 22, 2010
Corporate Releases

H. Lundbeck A/S held its Annual General Meeting on 20 April 2010 at the company's registered office

Apr 16, 2010
Corporate Releases

Update on legal proceedings

Apr 6, 2010
Corporate Releases

Novel agent for treatment of Parkinson's disease - Lu AE04621 - enters Lundbeck's development pipeline

Mar 26, 2010
Corporate Releases

Notice of the annual general meeting

Mar 19, 2010
Press Releases

Lundbeck appoints Senior Vice President for Business Development

Mar 16, 2010
Corporate Releases

Desmoteplase enters clinical phase II in Japan in ischaemic stroke representing Lundbeck's first clinical programme in Japan

Mar 15, 2010
Press Releases

Lundbeck appoints Senior Vice President for Legal

Mar 4, 2010
Corporate Releases

Fourth quarter and full year report 2009 - Lundbeck delivers 22 percent revenue growth for 2009 and meets financial expectations for 2009

Mar 3, 2010
Corporate Releases

Lundbeck and Takeda finalise plans to initiate phase III pivotal clinical trials with Lu AA21004 and Lu AA24530

Feb 25, 2010
Corporate Releases

Data from a post hoc analysis using desmoteplase in ischaemic stroke presented at the International Stroke Conference

Feb 24, 2010
Corporate Releases

Lundbeck expands the agreement with Teva to include marketing of Azilect® in selected Asian countries

Feb 5, 2010
Press Releases

Lundbeck appoints Vice President of Investor Relations and Communications

Jan 28, 2010
Press Releases

Lundbeck appoints Vice President of Group Finance

Jan 7, 2010
Corporate Releases

The European Commission opens proceedings

You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.